Abbott Laboratories (ABT) said Sunday its investigational, leadless Aveir Conduction System Pacing device showed safety and performance in a clinical feasibility study.
The device delivers conduction pacing to the heart's left bundle branch area by mimicking the heart's electrical rhythm, the company said.
Abbott also recently started enrolling patients in a clinical trial of up to 414 people to evaluate the safety and effectiveness of its investigational CSP Implantable Cardioverter-Defibrillator lead.
The US Food and Drug Administration recently granted breakthrough device designations to both the Aveir and CSP devices, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.